A head-to-head randomized controlled trial found similar remission rates for two leading biologic therapies for Crohn's disease: ustekinumab and adalimumab.
- Home
-
Specialtieschevron_right
- chevron_leftSpecialties
- Allergy, Immunology and Vaccinology
- Cardiology & Cardiovascular Surgery
- CTMS: Center for Transgender Medicine and Surgery
- Dermatology
- Diabetes & Endocrinology
- Gastroenterology, GI Surgery & Liver Diseases
- Genetics and Genomics
- Geriatrics
- Interventional Radiology
- Neurology & Neurosurgery
- Neurosurgery
- Nuclear Medicine
- Obstetrics and Gynecology
- Ophthalmology
- Orthopedics
- Occupational Medicine
- Oncology
- Otolaryngology (ENT) – Head and Neck Surgery
- Pediatrics: Mount Sinai Kravis Children's Hospital
- Psychiatry
- Pulmonology
- Rehabilitation
- Urology
- Specialty Reports
- COVID-19 Resources
- Contact Us
- About Us
- Mountsinai.org
- Find a Doctor
- Newsroom